Increased plasma visfatin concentrations in women with polycystic ovary syndrome

Fertility and Sterility

Volumn 88, Issue 2, 2007, Pages 401-405

  Chan, Te Fu ^a,b   Chen, Yi Ling ^b   Chen, Hung Hseng ^a,b   Lee, Chien Hung ^a   Jong, Shiang Bin ^b   Tsai, Eing Mei ^a,b  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

body mass index; polycystic ovary syndrome; Visfatin

Indexed keywords

ESTRADIOL; FOLLITROPIN; INSULIN; LUTEINIZING HORMONE; PROLACTIN; TESTOSTERONE; THYROTROPIN; VISFATIN;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ESTRADIOL BLOOD LEVEL; FEMALE; FOLLITROPIN BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; LUTEINIZING HORMONE BLOOD LEVEL; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RADIOIMMUNOASSAY; TESTOSTERONE BLOOD LEVEL; THYROTROPIN BLOOD LEVEL;

ADULT; BODY MASS INDEX; CASE-CONTROL STUDIES; CYTOKINES; FEMALE; HUMANS; POLYCYSTIC OVARY SYNDROME;

EID: 34547672910     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2006.11.120     Document Type: Article

References (32)

1. Polson D.W., Adams J., Wadsworth J., and Franks S. Polycystic ovaries-a common finding in normal women. Lancet 1 (1988) 870-872
2. Taylor A.E. Polycystic ovary syndrome. Endocrinol Metab Clin North Am 27 (1998) 877-902
3. Apter D., Butzow T., Laughlin G.A., and Yen S.S. Metabolic features of polycystic ovary syndrome are found in adolescent girls with hyperandrogenism. J Clin Endocrinol Metab 80 (1995) 2966-2973
4. Poretsky L., Cataldo N.A., Rosenwaks Z., and Giudice L.C. The insulin-related ovarian regulatory system in health and disease. Endocr Rev 20 (1999) 535-582
5. Bernasconi D., Del Monte P., Meozzi M., Randazzo M., Marugo A., Badaracco B., et al. The impact of obesity on hormonal parameters in hirsute and nonhirsute women. Metabolism 45 (1996) 72-75
6. Dunaif A., Segal K.R., Futterweit W., and Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 38 (1989) 1165-1174
7. Kirchengast S., and Huber J. Body composition characteristics and body fat distribution in lean women with polycystic ovary syndrome. Hum Reprod 16 (2001) 1255-1260
8. Montague C.T., and O'Rahilly S. The perils of portliness: causes and consequences of visceral adiposity. Diabetes 49 (2000) 883-888
9. Hoffstedt J., Wahrenberg H., Thorne A., and Lonnqvist F. The metabolic syndrome is related to beta 3-adrenoceptor sensitivity in visceral adipose tissue. Diabetologia 39 (1996) 838-844
10. Samal B., Sun Y., Stearns G., Xie C., Suggs S., and McNiece I. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol 14 (1994) 1431-1437
11. Hug C., and Lodish H.F. Medicine. Visfatin: a new adipokine. Science 307 (2005) 366-367
12. Fukuhara A., Matsuda M., Nishizawa M., Segawa K., Tanaka M., Kishimoto K., et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307 (2005) 426-430
13. Haider D.G., Schaller G., Kapiotis S., Maier C., Luger A., and Wolzt M. The release of the adipocytokine visfatin is regulated by glucose and insulin. Diabetologia 49 (2006) 1909-1914
14. Hammarstedt A., Pihlajamaki J., Rotter Sopasakis V., Gogg S., Jansson P.A., Laakso M., et al. Visfatin is an adipokine, but it is not regulated by thiazolidinediones. J Clin Endocrinol Metab 91 (2006) 1181-1184
15. Kralisch S., Klein J., Lossner U., Bluher M., Paschke R., Stumvoll M., et al. Interleukin-6 is a negative regulator of visfatin gene expression in 3T3-L1 adipocytes. Am J Physiol Endocrinol Metab 289 (2005) E586-E590
16. Bottcher Y., Teupser D., Enigk B., Berndt J., Kloting N., Schon M.R., et al. Genetic variation in the visfatin gene (PBEF1) and its relation to glucose metabolism and fat-depot-specific messenger ribonucleic acid expression in humans. J Clin Endocrinol Metab 91 (2006) 2725-2731
17. Ognjanovic S., Bao S., Yamamoto S.Y., Garibay-Tupas J., Samal B., and Bryant-Greenwood G.D. Genomic organization of the gene coding for human pre-B-cell colony enhancing factor and expression in human fetal membranes. J Mol Endocrinol 26 (2001) 107-117
18. Curat C.A., Wegner V., Sengenes C., Miranville A., Tonus C., Busse R., et al. Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia 49 (2006) 744-747
19. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 81 (2004) 19-25
20. Legro R.S., Kunselman A.R., Dodson W.C., and Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 84 (1999) 165-169
21. Carmina E., and Lobo R.A. Polycystic ovary syndrome (PCOS): arguably the most common endocrinopathy is associated with significant morbidity in women. J Clin Endocrinol Metab 84 (1999) 1897-1899
22. Krzyzanowska K., Krugluger W., Mittermayer F., Rahman R., Haider D., Shnawa N., et al. Increased visfatin concentrations in women with gestational diabetes mellitus. Clin Sci (Lond) 110 (2006) 605-609
23. Chen M.P., Chung F.M., Chang D.M., Tsai J.C., Huang H.F., Shin S.J., et al. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 91 (2006) 295-299
24. O'Meara N.M., Blackman J.D., Ehrmann D.A., Barnes R.B., Jaspan J.B., Rosenfield R.L., et al. Defects in beta-cell function in functional ovarian hyperandrogenism. J Clin Endocrinol Metab 76 (1993) 1241-1247
25. Ek I., Arner P., Ryden M., Holm C., Thorne A., Hoffstedt J., et al. A unique defect in the regulation of visceral fat cell lipolysis in the polycystic ovary syndrome as an early link to insulin resistance. Diabetes 51 (2002) 484-492
26. Rongvaux A., Shea R.J., Mulks M.H., Gigot D., Urbain J., Leo O., et al. Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis. Eur J Immunol 32 (2002) 3225-3234
27. Berndt J., Kloting N., Kralisch S., Kovacs P., Fasshauer M., Schon M.R., et al. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 54 (2005) 2911-2916
28. Kubota N., Terauchi Y., Yamauchi T., Kubota T., Moroi M., Matsui J., et al. Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 277 (2002) 25863-25866
29. Tafeit E., Moller R., Rackl S., Giuliani A., Urdl W., Freytag U., et al. Subcutaneous adipose tissue pattern in lean and obese women with polycystic ovary syndrome. Exp Biol Med (Maywood) 228 (2003) 710-716
30. Horejsi R., Moller R., Rackl S., Giuliani A., Freytag U., Crailsheim K., et al. Android subcutaneous adipose tissue topography in lean and obese women suffering from PCOS: comparison with type 2 diabetic women. Am J Phys Anthropol 124 (2004) 275-281
31. Strowitzki T., Halser B., and Demant T. Body fat distribution, insulin sensitivity, ovarian dysfunction and serum lipoproteins in patients with polycystic ovary syndrome. Gynecol Endocrinol 16 (2002) 45-51
32. Kitani T., Okuno S., and Fujisawa H. Growth phase-dependent changes in the subcellular localization of pre-B-cell colony-enhancing factor. FEBS Lett 544 (2003) 74-78